Skip to content
← All dividend stocks
HealthcareDrug Manufacturers - General

ABBV Dividend Calculator: Project AbbVie Dividend Income

AbbVie spun off from Abbott Laboratories in 2013 and has raised its dividend every year since, making it one of the fastest-growing large-cap payouts in health care. Immunology drugs anchor a portfolio that also spans neuroscience and aesthetics.

The much-discussed risk is patent expiry: Humira lost U.S. exclusivity in 2023, and the company is replacing that revenue with newer drugs. The payout is large relative to earnings, so pipeline execution matters for future increases.

Use this calculator to project ABBV income with or without reinvestment, model contributions, and work backwards from a monthly target.

Run ABBV in the calculatorCompare dividend ETFs

Data as of September 27, 2026 · Sources: Yahoo Finance and company filings.

Share price
$264.34
Dividend yield (TTM)
2.62%
TTM dividend / share
$6.83
Distribution frequency
Quarterly
Payout ratio
n/a
Market cap
$467.1B
How much ABBV do you need for your income goal?

Capital required at the current 2.62% yield, before taxes and before accounting for future dividend growth or reinvestment.

Monthly incomeAnnual incomeCapital requiredApprox. shares
$500/month$6.0K$229.0K867
$1,000/month$12.0K$458.0K1,733
$2,000/month$24.0K$916.0K3,466
$3,000/month$36.0K$1.4M5,199
$5,000/month$60.0K$2.3M8,664
$10,000/month$120.0K$4.6M17,327

Estimates only. Yield, share price, and distributions change over time. Use the full calculator to model monthly contributions, dividend growth, taxes, and reinvestment.

How long to reach your ABBV income goal?

Years until projected dividend income first reaches each target, starting from zero with every distribution reinvested. Assumes today's 2.62% yield and dividend growth consistent with the fund's record; taxes and withdrawals are excluded.

Monthly contribution$500/month$1,000/month$2,000/month$5,000/month
$250/month12 yr14 yr16 yr19 yr
$500/month9 yr12 yr14 yr17 yr
$1,000/month7 yr9 yr12 yr15 yr

Projections assume a constant yield, dividend growth consistent with the holding's recent record, no price changes beyond its recent trend, and full reinvestment. Actual results will differ. Dividend income is shown before taxes.

Who ABBV is for
  • Income investors who want health-care exposure with a rising payout
  • Investors willing to track drug patent cycles and pipeline news
  • Taxable accounts, since distributions are generally qualified
  • Portfolios pairing pharma income with consumer-staples stability
Trade-offs to understand
  • Large payout ratio leaves limited margin if key drugs lose exclusivity faster than replacements ramp
  • Drug pricing policy could pressure revenue
  • Clinical and regulatory outcomes are binary risks for pharma

About AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV key facts
MetricValue
CompanyAbbVie Inc.
SectorHealthcare
IndustryDrug Manufacturers - General
TickerABBV
Share price$264.34
Dividend yield (TTM)2.62%
Annual dividend / share$6.92
TTM distributions / share$6.83
Payout ration/a
Distribution frequencyQuarterly
Market cap$467.1B

Figures are the latest available and change with price and company reporting. The payout ratio is omitted when reported earnings distort it above 120% — common for REITs and companies with large one-off charges. Historical performance is not a forecast.

ABBV dividend history and payout schedule
TTM / share
$6.83
Yield (TTM)
2.62%
Annual growth
5.4%
Pays in
January, April, July, October
Payment datePer share
July 15, 2026$1.73
April 15, 2026$1.73
January 16, 2026$1.73
October 15, 2025$1.64
July 15, 2025$1.64
April 15, 2025$1.64
January 15, 2025$1.64
October 15, 2024$1.55

Annual growth compares the latest twelve months of distributions with the twelve months ending four years earlier and is not a forecast. Past distributions can be reduced or suspended.

ABBV frequently asked questions

ABBV yields about 2.62% per year on a trailing basis at $264.34 per share. The yield reflects a payout that has grown quickly since the 2013 spin-off from Abbott.

At a 2.62% yield, $12,000 per year requires roughly $458.0K, or about 1,733 shares at $264.34. Contributions and annual increases reduce the capital needed over time.

AbbVie distributes quarterly, recently in January, April, July, October. The trailing twelve-month distribution totals about $6.83 per share. Reinvestment is available automatically at most brokers.

Comparing the latest twelve months of distributions with the twelve months ending four years earlier, ABBV's per-share payout has grown at roughly 5.4% per year — among the faster rates in large-cap pharma. Increases are decided annually and are not guaranteed.

AbbVie has raised its dividend every year since 2013, supported by its immunology franchise and newer drugs replacing Humira revenue. The payout ratio is high, so a slower-than-expected pipeline ramp or drug-pricing pressure could limit future increases.

AbbVie's distributions are generally qualified dividends, taxed at long-term capital gains rates in taxable accounts. Holding ABBV in an IRA or Roth removes the annual tax drag. Confirm your own situation with a tax professional.

Investing $500 a month with all distributions reinvested, ABBV's projected dividend income reaches $1,000 a month in about 12 years. By then you would have contributed roughly $72.0K and the projected portfolio value would be about $361.6K. This assumes today's 2.62% yield and the growth assumptions shown in the calculator, with no taxes or withdrawals — projections, not guarantees.
Guides that go deeper
More stock calculators

Income goals

Disclaimer: This page is for educational purposes only and is not financial, investment, or tax advice. Data is sourced from Yahoo Finance and company filings and may be delayed or contain errors. Dividends are not guaranteed and can be reduced or suspended. Past performance is not indicative of future results. Always consult a qualified advisor before making investment decisions.